Loading…
Clinical-stage biotech developing oral small-molecule GLP-1 drugs for obesity and metabolic disease.
Clinical-stage biotech developing oral small-molecule GLP-1 drugs for obesity and metabolic disease.
Has no approved product and no partner revenue, so it is funded by selling shares to investors. Its research is split between South San Francisco and Shanghai. The case for its drug is a daily pill that avoids the injections used by most weight-loss drugs today.
Moat: none (IP / patents). Pre-commercial; competing against well-funded incumbents in the crowded oral GLP-1 obesity race.
Headquarters: South San Francisco, California, US · Founded: 2019 · Employees: 220
Size Structure Therapeutics, Inc. Sponsored ADR (GPCR) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $1.45B, the 2017th largest of 3,117 United States companies the cockpit tracks. Shares closed at $20.35 on 6 Nov 2026.
Performance Over six months the shares fell 48.0%, against -16.7% for the median peer and -1.1% for the United States market (cap-weighted) — 2nd lowest of 21 in its peer set.
Short interest Short interest is 10.0% of the free float (15 Oct 2026).
Next results Next results expected around 18 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$4.88M | -$3.90M | -$2.60M | -$949,174 | -$623,259 |
| EBITDA | -$364M | -$284M | -$156M | -$102M | -$51.9M |
| Net income | -$215M | -$142M | -$123M | -$89.5M | -$51.3M |
| Free cash flow | -$225M | -$226M | -$118M | -$81.6M | -$46.2M |
| Capital expenditure | $4.22M | $3.62M | $1.29M | $2.17M | $154,816 |
| Total debt | $6.23M | $6.49M | $3.86M | $5.45M | $260,001 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Structure Therapeutics, Inc. Sponsored ADR GPCR | $1.45B | -48% | n/a | n/a | n/a | n/a |
| Lilly (Eli) LLY | $1.27T | +43% | +46% | 51% | 15.2× | 5.9% |
| Novo Nordisk A/S NOVO-B.CO | $190B | -7% | +6% | 48% | 4.0× | 0.1% |
| Viking Therapeutics VKTX | $3.42B | -17% | n/a | n/a | n/a | n/a |
| Pfizer PFE | $168B | +14% | +1% | 26% | 3.4× | -4.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | GPCR | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -20.7% | -0.4% | 2nd lowest of 21 |
| 6-month return | -48.0% | -16.7% | 2nd lowest of 21 |
| Distance from 52-week high | -78.6% | -40.1% | 2nd lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Structure Therapeutics, Inc. Sponsored ADR GPCR | United States | $1.45B | -48% | n/a | n/a | n/a | n/a | n/a |
| Pacira Biosciences PCRX | United States | $1.45B | +57% | +6% | 4% | 2.2× | 14.9% | +11.1% |
| Marksans Pharma MARKSANS.NS | India | $1.45B | +50% | +24% | 20% | 3.9× | 31.6% | +16.6% |
| Ocular Therapeutix OCUL | United States | $1.45B | -32% | -8% | -603% | 17.9× | n/a | n/a |
| Damora Therapeutics DMRA | United States | $1.46B | -2% | n/a | n/a | n/a | n/a | n/a |
| Mabwell (Shanghai) Bioscience 688062.SS | China | $1.44B | -38% | +15% | -129% | 15.5× | n/a | n/a |
| Nippon Shinyaku 4516.T | Japan | $1.43B | -30% | +12% | 19% | 0.9× | -17.5% | +7.0% |
| Mezzion Pharma 140410.KS | South Korea | $1.42B | -29% | +7% | -223% | 226.6× | n/a | n/a |
| ABL Bio 298380.KS | South Korea | $1.49B | -73% | -64% | -251% | 55.7× | n/a | n/a |
| Zhejiang Jingxin Pharmaceutical 002020.SZ | China | $1.49B | -17% | +1% | 19% | 2.3× | -8.5% | +4.6% |
| Staidson (Beijing) Biopharmaceuticals 300204.SZ | China | $1.41B | -36% | -24% | -51% | 44.5× | n/a | n/a |
| Anupam Rasayan India ANURAS.NS | India | $1.40B | -15% | +52% | 16% | 5.2× | n/a | n/a |
| Shenzhen Chipscreen Biosciences 688321.SS | China | $1.40B | -33% | +27% | 12% | 8.9× | n/a | n/a |
| Zhejiang Hisoar Pharmaceutical 002099.SZ | China | $1.39B | -9% | +9% | -13% | 4.9× | n/a | n/a |
| Ascentage Pharma Group International 6855.HK | Hong Kong | $1.39B | -33% | +70% | -220% | 15.5× | n/a | n/a |
| Ultragenyx Pharmaceutical RARE | United States | $1.52B | +22% | +16% | -64% | 3.3× | n/a | n/a |
| Guangdong Taienkang Pharmaceutical 301263.SZ | China | $1.53B | -17% | +2% | -2% | 15.1× | n/a | n/a |
| Innoviva INVA | United States | $1.38B | -17% | +18% | 36% | 2.4× | -15.4% | +3.9% |
| Nanobiotix NANO.PA | France | $1.54B | -42% | -77% | -392% | 164.1× | n/a | n/a |
| Chongqing Lummy Pharmaceutical 300006.SZ | China | $1.55B | +53% | -6% | -19% | 13.6× | 49.9% | -13.2% |
| Indegene INDGN.NS | India | $1.56B | +15% | +36% | 12% | 3.3× | 29.6% | +29.4% |